Recently, Shanghai released the first list of recognized Specialized, Refined, Unique, and Innovative SMEs. Kylin Lab has been successfully included in this list due to its professional technical expertise and innovative achievements in the field of preclinical research and development for central nervous system (CNS) drugs.
来源：上海市经济和信息化委员会
Decoding Hanshu Biology's "Specialized, Refined, Unique, and Innovative" Attributes
1.Specialization Focus： We tackle high-barrier areas in CNS R&D, building differentiated competitiveness through deep expertise and specialized cultivation.
2.Refined Operations： An internationally compliant quality management system and high-standard experimental facilities have been established, supporting high-quality R&D through standardized processes and advanced hardware.
3.Unique Services： We provide end-to-end solutions for preclinical CNS drug development, offering personalized services tailored to diverse client needs. Our full-process empowerment and customized approaches meet multifaceted R&D demands.
4.Innovative Breakthroughs： With cutting-edge capabilities in animal model development, cell screening systems, electrophysiology platforms, AI-driven phenotypic screening, stem cells, and organoid models, we accelerate drug discovery through technological innovation.
Moving forward, Kylin Lab will continue to be guided by the "Specialized, Refined, Unique, and Innovative" principle, serving as an accelerator for CNS drug development in China. We are committed to addressing challenges in CNS disease treatment and bringing innovative therapies to patients sooner!
About Kylin Lab
CNSxplore | Pioneering CNS Drug Discovery--In vitro and in vivo, Beyond limits
Kylin Lab is a preclinical CRO company specializing in central nervous system (CNS) diseases, dedicated to offering one stop solutions for CNS drug discovery. With a portfolio of fully-validated cellular and animal disease models, combined with comprehensive research and analytical capabilities, we empower clients to accelerate the development of innovative therapies and reduce clinical trial risks.
Kylin Lab boasts an experienced technical team well-versed in international regulations, along with high-standard experimental platforms. Our core technologies include AI-driven phenotypic screening, humanized stem cells and organoids, electrophysiology, high-throughput electroencephalography (EEG), histology, and molecular biology. Our expertise spans a broad range of areas including Alzheimer’s disease, Parkinson’s disease, depression, schizophrenia, spinal muscular atrophy (SMA), pain, and stroke etc.
Since its establishment, Kylin Lab has adhered to the philosophy of “Pioneering R&D, Leading in technology Quality-first, Customer-centric.” We have served hundreds of clients, successfully completed numerous thematic research projects and IND submissions, and established a high-quality, stable, and forward-looking efficacy evaluation system.
